NO20025007D0 - Hemostatisk aktivt vWF-inneholdende preparat og fremgangsmåte for fremstilling derav - Google Patents

Hemostatisk aktivt vWF-inneholdende preparat og fremgangsmåte for fremstilling derav

Info

Publication number
NO20025007D0
NO20025007D0 NO20025007A NO20025007A NO20025007D0 NO 20025007 D0 NO20025007 D0 NO 20025007D0 NO 20025007 A NO20025007 A NO 20025007A NO 20025007 A NO20025007 A NO 20025007A NO 20025007 D0 NO20025007 D0 NO 20025007D0
Authority
NO
Norway
Prior art keywords
vwf
preparation
fraction
active
composition
Prior art date
Application number
NO20025007A
Other languages
English (en)
Other versions
NO20025007L (no
NO324773B1 (no
Inventor
Djuro Josic
Monika Andrea Stadler
Gerhard Gruber
Original Assignee
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octapharma Ag filed Critical Octapharma Ag
Publication of NO20025007D0 publication Critical patent/NO20025007D0/no
Publication of NO20025007L publication Critical patent/NO20025007L/no
Publication of NO324773B1 publication Critical patent/NO324773B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20025007A 2000-04-18 2002-10-17 Hemostatisk aktivt vWF-inneholdende preparat og fremgangsmate for fremstilling derav NO324773B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00108430A EP1148063A1 (de) 2000-04-18 2000-04-18 Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
PCT/EP2001/003819 WO2001079260A1 (de) 2000-04-18 2001-04-04 Haemostatisch aktives vwf enthaltendes präparat und verfahren zu seiner herstellung

Publications (3)

Publication Number Publication Date
NO20025007D0 true NO20025007D0 (no) 2002-10-17
NO20025007L NO20025007L (no) 2002-11-28
NO324773B1 NO324773B1 (no) 2007-12-10

Family

ID=8168496

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025007A NO324773B1 (no) 2000-04-18 2002-10-17 Hemostatisk aktivt vWF-inneholdende preparat og fremgangsmate for fremstilling derav

Country Status (24)

Country Link
US (2) US7166709B2 (no)
EP (2) EP1148063A1 (no)
JP (1) JP4976634B2 (no)
KR (1) KR100685448B1 (no)
CN (1) CN100448888C (no)
AT (1) ATE306494T1 (no)
AU (2) AU6383501A (no)
BR (1) BR0110193A (no)
CA (1) CA2406626C (no)
CZ (1) CZ303932B6 (no)
DE (1) DE50107689D1 (no)
DK (1) DK1274721T3 (no)
EA (1) EA006209B1 (no)
EE (1) EE200200595A (no)
ES (1) ES2247117T3 (no)
HU (1) HU225992B1 (no)
IL (2) IL152173A0 (no)
MX (1) MXPA02010017A (no)
NO (1) NO324773B1 (no)
RS (1) RS50835B (no)
SI (1) SI1274721T1 (no)
UA (1) UA76714C2 (no)
WO (1) WO2001079260A1 (no)
ZA (1) ZA200208396B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
ITLU20070007A1 (it) * 2007-05-07 2008-11-08 Kedrion Spa Processo cromatografico per l'ottenimento di un complesso fviii/vwf con differenti rapporti tra le due proteine da utilizzare nella terapia della emofilia a e nella malattia di von willebrand.
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
CN105816858A (zh) 2007-12-28 2016-08-03 巴克斯特国际公司 重组vwf配方
KR101648734B1 (ko) 2008-06-24 2016-08-18 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
AU2009307648C1 (en) 2008-10-21 2016-12-08 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
IT1396528B1 (it) * 2009-01-19 2012-12-14 Kedrion Spa Nuovo processo di purificazione altamente selettivo di due proteine plasmatiche: von willebrand factor (vwf) e fibronectina (fn).
AU2011260258B2 (en) * 2010-06-01 2015-07-09 Baxter Healthcare S.A. Process for making dry and stable hemostatic compositions
JP2013537215A (ja) 2010-09-20 2013-09-30 オクタファルマ・アーゲー フィブリノーゲンの生産方法
WO2012082933A1 (en) 2010-12-15 2012-06-21 Baxter International, Inc. Eluate collection using conductivity gradient
US10064406B2 (en) * 2011-01-06 2018-09-04 Cytosorbents Corporation Polymeric sorbent for removal of impurities from whole blood and blood products
ES2642383T3 (es) 2012-03-13 2017-11-16 Octapharma Ag Procedimiento mejorado de producción de fibrinógeno y fibrinógeno producido por el mismo
EP2841451A1 (en) 2012-04-24 2015-03-04 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
EP0367840B1 (de) 1988-11-05 1993-02-03 Octapharma AG Verfahren zur Herstellung eines hochreinen, nicht infektiösen Antihämophiliefaktors mittels Chromatographie
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
FR2681867B1 (fr) * 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
DE4204694C3 (de) * 1992-02-01 1995-10-12 Octapharma Ag Verfahren zur Gewinnung von hochreinem, virusinaktiviertem Faktor VIII mittels Anionenaustauscher-Chromatographie
EP0674531A1 (de) * 1992-12-16 1995-10-04 IMMUNO Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT404358B (de) * 1997-02-04 1998-11-25 Immuno Ag Verfahren zur chromatographischen reinigung bzw. fraktionierung von von willebrand-faktor aus einem vwf-hältigen ausgangsmaterial
US6531577B1 (en) * 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung

Also Published As

Publication number Publication date
US7985846B2 (en) 2011-07-26
EA200201104A1 (ru) 2003-04-24
EP1148063A1 (de) 2001-10-24
IL152173A (en) 2007-07-24
IL152173A0 (en) 2003-05-29
CN1425024A (zh) 2003-06-18
EP1274721A1 (de) 2003-01-15
EP1274721B1 (de) 2005-10-12
EA006209B1 (ru) 2005-10-27
CZ303932B6 (cs) 2013-07-03
BR0110193A (pt) 2003-02-11
CA2406626A1 (en) 2001-10-25
NO20025007L (no) 2002-11-28
CN100448888C (zh) 2009-01-07
RS50835B (sr) 2010-08-31
HUP0301211A3 (en) 2005-12-28
SI1274721T1 (sl) 2006-04-30
NO324773B1 (no) 2007-12-10
JP4976634B2 (ja) 2012-07-18
KR20030019352A (ko) 2003-03-06
YU78402A (sh) 2006-08-17
DK1274721T3 (da) 2006-02-13
MXPA02010017A (es) 2003-04-25
CA2406626C (en) 2012-02-21
JP2004516231A (ja) 2004-06-03
ES2247117T3 (es) 2006-03-01
AU6383501A (en) 2001-10-30
US20070232791A1 (en) 2007-10-04
KR100685448B1 (ko) 2007-02-23
HU225992B1 (en) 2008-02-28
ATE306494T1 (de) 2005-10-15
WO2001079260A1 (de) 2001-10-25
PL358388A1 (en) 2004-08-09
CZ20023454A3 (cs) 2003-05-14
US20030138913A1 (en) 2003-07-24
ZA200208396B (en) 2004-04-30
US7166709B2 (en) 2007-01-23
HUP0301211A2 (hu) 2003-07-28
EE200200595A (et) 2004-04-15
DE50107689D1 (de) 2006-02-23
AU2001263835B2 (en) 2005-06-09
UA76714C2 (uk) 2006-09-15

Similar Documents

Publication Publication Date Title
NO20025007D0 (no) Hemostatisk aktivt vWF-inneholdende preparat og fremgangsmåte for fremstilling derav
DE69328519T2 (de) Chondroitinase, Herstellungsverfahren und pharmazeutische Zusammensetzung
AU5465498A (en) Analysis and separation of platelet-derived growth factor proteins
DE69626521T2 (de) Konzentrierte, stabile textilweichmacherzusammensetzung
ATE277073T1 (de) Verfahren und vorrichtung zur herstellung von gereinigten plasmaproteinen
BR9004626A (pt) Processo para preparar um concentrado estavel de complexo de fator viii-fator de von willebrand,concentrado de complexo de fator viii-fator de von willebrand e concentrados de proteina derivados de plasma
DE69803570D1 (de) Bipolare elektrolyseur mit ionenaustauscher membran
DK0659767T3 (da) Fremgangsmåde til fremstilling af et koncentrat af anti-D-immunoglobulin G og et farmaceutisk præparat, som indeholder dett
DK0646594T3 (da) Fremgangsmåde til rensning af proteiner
DK0567448T3 (da) Fremgangsmåde til fremstilling af faktor VIII
US5071961A (en) Method of enrichment of coagulation factors ii, vii, ix and x
ATE214618T1 (de) Desinfektion durch partikelgebundene und insolubilisierte detergentien
CA2096888A1 (en) Process for the inactivation of viruses in preparations of proteins
Barington et al. A Very‐High‐Purity von Willebrand Factor Preparation Containing High‐Molecular‐Weight Multimers
DK59785D0 (da) Fremgangsmaade til fremstilling af i det vaesentlige fibrinogenfrit ahf
DE69637278D1 (de) Methode zur herstellung von thrombin
KR960023054A (ko) 재조합 인간 에리스로포이에틴의 정제 방법
DK0786476T3 (da) Sammensætning og fremgangsmåde til limning af plane strukturer
KR930000679A (ko) 한국형 c형 간염 바이러스의 특이항원인 khcv ub-코아(ocre) 14단백질의 정제 방법
KR940014804A (ko) 삼상분할법을 이용한 아미노펩티다제의 정제방법
DE59707174D1 (de) Verfahren zur weiterleitung mit 100% leitungsauslastung von asynchron übertragenen nachrichtenzellen

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees